Shots:

• NanoString to receive $40M in cash & $10M in Veracyte’s stock along with $10M as milestones.  Veracyte to get an exclusive global right to develop and commercialize diagnostic tests on NanoString’s nCounter FLEX system
• Veracyte will expand nCounter-based diagnostic portfolio utilizing its own test and has obtained rights to NanoString's 510(k)-cleared Prosigna breast cancer prognostic test and research-use LymphMark lymphoma assay and will distribute the nCounter FLEX system for diagnostic purposes
• NanoString will retain an exclusive right to commercialize nCounter products and will manufacture test kits for Prosigna- LymphMark and new tests developed by Veracyte or its partners for use on the nCounter FLEX platform. Additionally- Veracyte will buy diagnostic assay kits and nCounter systems under a different supply agreement

Click here to­ read full press release/ article | Ref: Businesswire | Image: Owler